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Abstract
Objective: To determine the feasibility and safety of implementing a 12-week rehabilitation program after mesenchymal stromal cell (MSC)
transplantation augmented by vascularized bone grafting for idiopathic osteonecrosis (ION) of the femoral head.
Design: A prospective case series.
Setting: University clinical research laboratory.
Participants: Participants (NZ10) with ION who received MSC transplantation augmented by vascularized bone grafting.
Intervention: A 12-week exercise program, which included range-of-motion (ROM) exercises, muscle-strengthening exercises, and aerobic training.
Main Outcome Measures: Measures of ROM, muscle strength, Timed Up and Go test, and Medical Outcomes Study 36-Item Short-Form Health
Survey (SF-36) were collected before surgery and again at 6 and 12 months after surgery.
Results: All participants completed the 12-week program. External rotation ROM as well as extensor and abductor muscle strength significantly
improved 6 months after treatment compared with that before treatment (P<.05). Significant improvements were also seen in physical function,
role physical, and bodily pain subgroup scores of the SF-36 (P<.05). No serious adverse events occurred.
Conclusions: This study demonstrates the feasibility and safety of a multiplex rehabilitation program after MSC transplantation and provides
support for further study on the benefits of rehabilitation programs in regenerative medicine.
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http://dx.doi.org/10.1016/j.apmr.2014.09.040Idiopathic osteonecrosis (ION) of the femoral head is a painful
disorder that progresses to femoral head collapse and osteoarthritis
of the hip joint.1,2 This disease mainly affects individuals aged 30
to 40 years.3 The exact pathologic mechanism of ION remains
unknown; however, obstruction of blood flow to the femoral head,
which causes death of bone-forming cells, is a hallmark of this
condition. Without bone-forming cells, bone tissue gradually losesOpen access under CC BY-NC-ND license.
Rehabilitation program after stem cell transplantation 533its mechanical properties and eventually collapses, causing artic-
ular surface deformities.1-3
Recently, surgical treatment has become more common than
nonsurgical treatment for ION in the United States.4 Conservative
treatment to offload forces by limiting weight-bearing, activity
modification, and physical therapy is thought to have limited
success in preventing disease progression.3,4 If the disease pro-
gresses, the patient eventually requires total hip arthroplasty
(THA).1-3 Although the survival rate of THA has improved
markedly, individuals with ION are typically young, and THA
durability is limited; therefore, joint-preserving treatment is
preferred. However, recent data indicate that joint-preserving
procedures are performed less often than THA.3
Regenerative medicine using cell transplantation is a prom-
ising treatment for patients with refractory disease. Mesenchymal
stromal cell (MSC) transplantation, for example, is a promising
new treatment for joint preservation in ION. MSCs can differen-
tiate into cells of osteogenic, chondrogenic, and adipogenic line-
ages in vitro.5-7 During early-stage ION, treatment with MSCs in
combination with core decompression surgery has resulted in
significant delay and even prevention of femoral head collapse.8-12
However, in more advanced stages, the result of this procedure has
not been satisfactory.12-14 Because bone marrow pressure is
elevated in the early stage of ION,15 core decompression to reduce
the pressure is required. However, in advanced-stage disease,
when subchondral bone fractures occur, initial strengthening,
instead of decompression, is needed to prevent collapse.16
We designed a protocol using a combination of MSCs and
vascularized bone grafts for treating advanced stages of ION.17
Because ION is caused by loss of blood supply and bone-
forming cells as well as mechanical vulnerability, vascularized
bone grafting is, theoretically, a reasonable treatment for this
condition.16,17 Although MSC transplantation is a promising
therapeutic strategy, rehabilitation interventions after surgery may
have a significant effect on the ultimate treatment result. However,
detailed information about rehabilitation programs after cell
transplantation has not yet been reported.8-14 Moreover, the effect
of rehabilitation alone on ION is controversial.18,19 This study
aimed to determine the feasibility and safety of a rehabilitation
program that was performed in a clinical trial of MSC trans-
plantation augmented by vascularized bone grafting for ION.
Methods
The current study was a prospective case series of subjects
enrolled in a clinical trial. Details of this prospective, open-
labeled, proof-of-concept clinical trial, conducted at Kyoto Uni-
versity Hospital, have been previously reported.17 The study
protocol was approved by the Ethics Committee of Kyoto Uni-
versity Graduate School and Faculty of Medicine and was con-
ducted according to the Declaration of Helsinki. For this clinical
trial, participants were recruited via the website page of KyotoList of abbreviations:
ION idiopathic osteonecrosis
MSC mesenchymal stromal cell
RM repetition maximum
ROM range of motion
SDIC Specific Disease Investigation Committee
SF-36 Medical Outcomes Study 36-Item Short-Form Health
Survey
THA total hip arthroplasty
www.archives-pmr.orgUniversity Hospital and the University Hospital Medical Infor-
mation Network (UMIN) Clinical Trials Registry.
Assessment of necrotic lesion and radiographic
stage
Necrotic lesion type and size were assessed using the radiographic
classification proposed by the Specific Disease Investigation Com-
mittee (SDIC) in Japan (appendix 1).20 Staging of ION proposed by
the SDIC in Japan is a modified version of the system proposed by
the Association Research Circulation Osseous Committee.20
Inclusion criteria
Patients aged 20 to 50 years with radiographic stage 3A or 3B,
according to SDIC staging,20 were eligible for enrollment. Written
informed consent was obtained from all participants in the clin-
ical trial.
Exclusion criteria
Exclusion criteria were a history of transplantation on the affected
part of the hip, heavy smoking (Brinkman index >600), current
use of warfarin, diabetes mellitus (defined as hemoglobin A1c
>9.0%), arteriosclerosis obliterans, pregnancy, malignant disease,
myocardial infarction, brain infarction, rheumatoid arthritis,
dialysis use, hematologic disease (leukemia, myeloproliferative
disorder, myelodysplastic disorder), limited life expectancy, hep-
atitis B, hepatitis C, human immunodeficiency virus infection,
syphilis, hypotension (systolic blood pressure <90mmHg), low
body weight (<40kg), loss of marrow function (neutrophil count
<1500/mm3, hemoglobin level <11.0g/dL [men] or <10.0g/dL
[women], platelet count <100,000/mm3), change in medication
(bisphosphonates or steroids) within 3 months of the study, and
ineligibility determined by a doctor.
MSC transplantation augmented by vascularized
bone grafting
Under general anesthesia, 100mL of bone marrow was obtained
from the posterior iliac crest. Mononuclear cells containing MSCs
were cultured for approximately 2 weeks under 20% partial
pressure of oxygen (PO2) and 5% partial pressure of carbon di-
oxide (PCO2) conditions at 37
C.
MSC transplantation was augmented by vascularized bone
grafting. Briefly, participants were placed on the table in the su-
pine position. A curved skin incision (modified Smith-Peterson
approach) was made from the iliac crest to the anterior aspect of
the proximal thigh.17 The rectus femoris was released, and the
anterior aspect of the femoral neck was explored. Then, a cortical
window (1.54cm) was prepared, through which a bony trough
connecting the necrotic area was created under both fluoroscopic
and endoscopic guidance. MSCs (0.5e1.5108) premixed with
b-tricalcium phosphate granules (Osferiona) were transplanted
into the cavity created by curettage. Tricortical iliac crest bone
was harvested with a vascular pedicle and grafted into the bone
trough.16 Then, the joint capsule and rectus femoris were sutured.
Rehabilitation program
Rehabilitation was performed at a hospital for 12 weeks. During the
initial 4 weeks, rehabilitationwas performed at an acute care hospital
(table 1). Participants continued rehabilitation at a special rehabili-
tation hospital for 8 additional weeks. During the first 4 weeks,
Table 1 Rehabilitation program
Time Course
After Treatment Side Day 1 Day 3 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 8 Week 10 Week 12 Discharge
Rest level Bed rest Wheelchair Walk on
crutch
! Walk on T-cane
Weight-bearing NWB ! 1/3 WB 1/2 WB 2/3 WB FWB
ROM exercise Transplant Passive
F, E!
Passive
Ab
!
Passive R!
Active F, E, Ab, R
Nontransplant Passive & active F, E, Ab, R
!
Muscle strength
exercise
Transplant Isotonic (Straight leg raising, no
weight)!
Isotonic (Straight leg raising,
2-kg weight)
Isokinetic
F, E!
Isokinetic
Ad!
Isokinetic R!
Isokinetic Ab
Squat & heel raise
Nontransplant Isometric
F, E, Ab, R
!
Isokinetic F, E, Ab, R
Squat & heel
raise
!
Muscle strength exercise of upper limb
!
Aerobic training Aerobike!
Abbreviations: Ab, abduction; Ad, adduction; E, extension; F, flexion; FWB, full weight-bearing; NWB, noneweight-bearing; R, rotation; WB, weight-bearing.
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Rehabilitation program after stem cell transplantation 535physical therapywasperformed for 40minutes at a time, once a day, 5
days a week. After the initial 4 weeks, it was performed for 60 mi-
nutes at a time, twice a day, 6 days a week. The entire rehabilitation
program was supervised by skilled physiotherapists, and the specific
therapy received was recorded in the participant’s medical record.
Participants were kept noneweight-bearing for 6 weeks after
transplantation surgery, followed by one-third weight-bearing,
one-half weight-bearing, and two-thirds weight-bearing, pro-
gressing at 2-week intervals (see table 1). Full weight-bearing was
permitted 12 weeks after treatment.
Before performing range-of-motion (ROM) exercises, pain
level was assessed using a numeric rating scale. Passive flexion
and extension ROM exercises were initiated 2 weeks after treat-
ment on the transplant side. Passive adduction was initiated 3
weeks after treatment, and passive rotation ROM exercise was
initiated 6 weeks after treatment. Active ROM exercise in all
directions was initiated 12 weeks after treatment (see table 1).
Passive and active ROM exercises in all directions were initiated 3
days after treatment on the nontransplant side (see table 1).
For isotonic flexion muscle-strengthening exercise, straight
leg raising with no weight was started 6 weeks after treatment on
the transplant side (see table 1). Straight leg raising with 2-kg
weight was started after 10 weeks. The intensity of exercise
was defined by pain level. Each position was held for 5 seconds
and performed 5 times. For isokinetic flexion and extension
muscle-strengthening exercises, resistance training was started 6
weeks after treatment on the transplant side. The intensity of
exercise was increased by increasing the load by 40% to 80% of
10-repetition maximum (RM). Isokinetic adduction exercise was
added at 8 weeks, rotation exercise at 10 weeks, and adduction
exercise at 12 weeks after treatment. Isokinetic rotation exercise
was performed using Coxa Link.b Squat and heel raise exercises
were performed 12 weeks after treatment. On the nontransplant
side, isometric and isokinetic exercises were started 3 days after
treatment. If muscle weakness was present, the intensity of ex-
ercise was increased by increasing the load by 70% to 100% of
10RM for muscular hypertrophy. If muscle weakness was not
present, exercise loading was increased by 60% to 70% of 15RM
for muscular endurance. Nontransplant side squat and heel raise
exercises were started 6 weeks after treatment. Upper limb
muscle-strengthening exercises were performed using Shoulder
Linkb 1 week after treatment (see table 1).
Aerobic training was started 8 weeks after treatment. The
intensity of exercise was defined as a target heart rate of
220(age0.6) by using an Aerobike Aic for 30 minutes. After
discharge, participants continued home exercises and were
assessed once a month. Patients were allowed to resume sports
and work 6 months after confirmation of bone ossification
(see table 1).
Assessment
All participants underwent assessment before treatment and 6 and
12 months after treatment. Passive hip flexion, extension, abduc-
tion, and external rotation angles were measured using universal
goniometry. Hip flexor, extensor, and abductor strengths were
measured using a handheld dynamometerd during isometric
contraction for 3 seconds with manual resistance. Knee extensor
and flexor strengths and lower limb load were assessed using the
Iso Force GT-330.e Torque was expressed as a percentage of body
weight (Nm/kg). Values of lower limb load force were normalized
to body weight (N/kg). In the Timed Up and Go test, the time (inwww.archives-pmr.orgseconds) that a participant required to stand from an armless chair
(chair seat height, 45cm), walk a distance of 3m, turn, walk back
to the chair, and sit down was measured. Health-related quality of
life was evaluated using the Medical Outcomes Study 36-Item
Short-Form Health Survey (SF-36).21
Adverse events
Compliance with the rehabilitation program and adverse events
were recorded in each participant’s medical record. Adverse
events were monitored by the Department of Clinical Trial
Design and Management Translational Research Center. Serious
adverse events were assessed by the External Data Moni-
toring Committee.
Statistical analysis
ROM, muscle strength, and SF-36 score were presented as the
median with 25% to 75% quartiles. For follow-up assessment of
changes in each outcome over time, the Friedman test was used to
identify overall significant differences at 3 different time points
(before treatment and 6 and 12mo after treatment) for each vari-
able. Post hoc Scheffe test was used to assess which time points
showed significant differences. A P value of <.05 was considered
statistically significant for all analyses.
Results
Between November 2007 and June 2009, 10 participants were
recruited into the clinical trial. All participants were men with an
average age of 31.7 years (range, 20e48y). A history of steroid
treatment was found in 4 participants (table 2). The pretreatment
radiographic stage was 3A in 6 hips and stage 3B in 4 hips (see
table 2). During the rehabilitation period (6mo after surgery),
there was no progression of disease. At 1 year after surgery, 6 hips
with stage 3A and 2 hips with stage 3B did not progress, but 2 hips
with stage 3B (cases 3 and 7) progressed to stage 4.17
Hip ROM
While nearly all ROM measures improved after treatment, the
only significant improvements were transplant-side external rota-
tion at 6 months (P<.05) and nontransplant-side flexion at 12
months (P<.01) (table 3).
Muscle strength and function
While nearly all muscle strength measures improved after treat-
ment, the only significant improvements were transplant-side
extensor and abductor strength at 12 months after treatment
(P<.05) (table 4).
On the nontransplant side, there was significant improvement
in lower limb load strength (P<.05) (see table 4). The remaining
subgroup scores showed posttreatment improvements that did not
reach statistical significance.
SF-36 subgroup score
There were significant improvements in physical function, role
physical, and bodily pain subgroup scores between the 3 time
points (before treatment and 6 and 12mo after treatment)
(P<.05) (table 5). There was also a significant difference in each
score between values before and 12 months after treat-
ment (P<.05).
Table 2 Baseline data of patients
Case Age (y) Sex Height (cm) Weight (kg) Affected Side Steroid Use Class* Stagey History
1 27 M 170.9 66.5 R Y C2 3B Nephritis
2 23 M 171.0 56.6 L Y C2 3A Cushing syndrome
3 48 M 174.7 87.5 R N C2 3B Meningioma
4 20 M 174.2 76.8 R Y C1 3A Hepatitis
5 35 M 178.8 70.0 L N C2 3A None
6 28 M 169.2 58.3 R N C2 3A None
7 39 M 183.1 85.2 R Y C2 3B Leukemia
8 26 M 175.1 66.4 R N C2 3B None
9 33 M 174.2 61.0 R N C2 3A None
10 38 M 166.7 52.9 R N C2 3A None
Abbreviations: L, left; M, male; N, no; R, right; Y, yes.
* Radiographic clinical classification proposed by Japanese Investigation Committee.
y Radiographic staging score by Japanese Investigation Committee.
536 T. Aoyama et alAdverse events
All participants completed the 12-week rehabilitation program.
There were 5 cases of muscle pain, 2 cases of muscle stiffness, and
1 case of ankle pain on initiation of load bearing, but no serious
adverse events were associated with rehabilitation. Radiography
showed no evidence of progression in femoral head collapse
during the rehabilitation period.
Discussion
In the current study, we designed a rehabilitation program that
focused on 3 aspects: (1) improving hip joint function, (2)
avoiding collapse of the femoral head, and (3) promoting bone
formation from transplanted cells by using a physical ther-
apy protocol.
In the field of rehabilitation, the relationship between pursuing
functional improvement and risk reduction becomes a trade-off in
some cases, but compatibility between them is important. To
accomplish this trade-off, it is helpful to simultaneously assess theTable 3 Comparison of hip ROM between pretreatment, 6 months afte
Hip ROM Pretreatment 6mo After Treatment
E
(
Flexion (deg)
Transplant side 97.5 (95.0e107.5) 107.5 (96.3e110.0) .
Nontransplant side 101.0 (100.0e110.0) 112.5 (100.0e113.8) .
Extension (deg)
Transplant side 20.0 (15.0e20.0) 20 (16.3e20.0) .
Nontransplant side 20.0 (16.3e20.0) 20.0 (15.0e20.0) .
Abduction (deg)
Transplant side 30.0 (21.3e35.0) 35.0 (30.0e40.0) .
Nontransplant side 35.0 (31.3e38.8) 37.5 (31.3e40.0) .
External rotation (deg)
Transplant side 45.0 (37.5e53.8) 50.0 (41.3e60.0)y .
Nontransplant side 40.0 (37.5e53.8) 50.0 (45.0e60.0) .
NOTE. Values are median (25%e75% quartiles) or as otherwise indicated.
comparison test was performed by Scheffe test.
* P<.01.
y P<.05 as calculated by comparison with pretreatment.etiologic factors and radiologic findings of these patients in order
to treat ION.22,23 Further, lesion size, lesion location, and radio-
graphic staging can help determine the natural course of ION.22 In
our patients, necrotic lesion size was broad, and radiographic stage
had progressed (see table 2). The prognosis for steroid-induced
ION is better than that for ION associated with sickle cell ane-
mia.22 In our study, among the 10 participants, 4 had a history of
steroid use, while the other 6 had idiopathic ION (see table 2). The
rehabilitation program in patients with ION should consider these
aspects and should be planned carefully to avoid collapse of the
femoral head.
Weight-bearing was prohibited until 6 weeks after treatment
(see table 1), and full-weight sitting-to-standing actions were
prohibited until 12 weeks after treatment because of the high
pressure placed on the top of the femoral head.24-26 Not only
weight-bearing, but also muscle activity increases the acetabular
contact pressure. Isometric hip extension and active hip flexion
generate high pressure on the femoral head, equal to weight-
bearing and walking.25,26 By comparison, the pressure generated
by isotonic and isokinetic exercises is much less.25,26 Such joint-r treatment, and 12 months after treatment (NZ10)
ffect Size
Pre/6mo)
12mo After
Treatment
Effect Size
(Pre/12mo)
P at 3 Time Points
(Pre/6mo/12mo)
58 107.5 (100e113.8) .74 .19
31 112.5 (101.3e120.0)* .47 <.01
12 15.0 (15.0e18.8) .47 .34
01 17.5 (15.0e20.0) 0 .92
52 35.0 (30.0e38.8) .38 .24
23 35.0 (35.0e35.0) .11 .53
43 50.0 (42.5e53.8) .31 .09
46 50.0 (45.0e60.0) .42 .38
P values at 3 time points were calculated by Friedman test. Multiple
www.archives-pmr.org
Table 4 Comparison of physical function between pretreatment, 6 months after treatment, and 12 months after treatment (NZ10)
Measure Pretreatment 6mo After Treatment
Effect Size
(Pre/6mo)
12mo After
Treatment
Effect Size
(Pre/12mo)
P at 3 Time
Points
(Pre/6mo/
12mo)
Hip flexor strength (Nm/kg)
Transplant side 1.39 (1.01e1.65) 1.49 (1.35e1.86) 0.74 1.79 (1.58e1.91) 0.70 .12
Nontransplant side 1.30 (1.05e1.50) 1.82 (1.38e1.96) 1.14 1.73 (1.68e2.03) 1.12 .08
Hip extensor strength (Nm/kg)
Transplant side 0.56 (0.43e0.78) 1.48 (0.84e1.56) 0.98 1.28 (0.86e1.69)* 1.00 <.05
Nontransplant side 0.64 (0.37e0.80) 1.13 (0.82e1.49) 1.18 1.61 (0.96e1.77) 1.62 .08
Hip abductor strength (Nm/kg)
Transplant side 0.67 (0.51e1.29) 1.20 (0.81e1.43) 0.58 1.28 (1.05e1.78)* 0.86 <.05
Nontransplant side 0.66 (0.52e1.37) 1.21 (0.88e1.66) 0.53 1.28 (1.21e1.85) 0.71 .20
Knee flexor strength (Nm/kg)
Transplant side 1.36 (1.18e1.79) 1.55 (1.32e1.81) 0.38 1.63 (1.37e1.71) 0.47 .15
Nontransplant side 1.36 (1.11e1.70) 1.50 (1.12e1.66) 0.29 1.55 (1.27e1.58) 0.37 .07
Knee extensor strength (Nm/kg)
Transplant side 2.77 (2.24e3.37) 2.97 (2.42e4.09) 0.46 3.22 (2.93e3.69) 0.56 .10
Nontransplant side 2.71 (2.50e4.00) 3.38 (2.98e3.83) 0.49 3.51 (2.72e4.10) 0.36 .19
Lower limb load (N/kg)
Transplant side 10.61 (8.01e14.58) 15.78 (9.16e20.02) 0.99 15.34 (12.04e19.74) 0.98 .06
Nontransplant side 14.16 (10.36e20.65) 17.61 (12.49e21.72) 0.47 18.04 (14.12e23.50)* 0.70 <.05
Timed Up and Go test (s) 7.06(5.82e7.31) 6.11 (4.96e7.00) 0.51 5.40 (5.00e6.50) 0.77 .15
NOTE. Values are median (25%e75% quartiles) or as otherwise indicated. P values at 3 time points were calculated by Friedman test. Multiple
comparison test was performed by Scheffe test.
* P<.05, as calculated by comparison with pretreatment.
Rehabilitation program after stem cell transplantation 537preserving, muscle-strengthening exercise has been reported in
physical therapy for osteoarthritis.27,28 We designed the rehabili-
tation program so that isotonic and isokinetic exercises could be
performed on the transplant side before isometric exercises (see
table 1). All participants completed the 12-week rehabilitation
program without excessive pain. Functional improvement was
observed, and there were no serious adverse events associated with
rehabilitation. These results suggest that the first 2 aims of our
study were achieved.
Although we could not show clear evidence that the current
rehabilitation program promotes bone formation, mechanical
stimulation may be important for bone formation ofTable 5 Comparison of SF-36 subgroups scores between pretreatment
SF-36
Subgroups Pretreatment
6mo After
Treatment
Effect
(Pre/
Physical function 45 (36.3e65) 90 (78.8e95) 1.54
Role-physical 40.6 (36.3e78.1) 68.8 (57.8e93.8) 0.71
Bodily pain 52 (51.3e52) 72 (64.5e72) 2.83
General health 59.5 (49.5e77) 77 (61.8e90.8) 0.66
Vitality 71.9 (54.7e84.4) 68.8 (62.5e84.4) 0.22
Social function 31.3 (25e84.4) 100 (71.9e100) 0.90
Role-emotion 50 (37.5e87.5) 100 (100e100) 0.89
Mental health 80 (71.2e88.8) 90 (82.5e90) 0.52
NOTE. Values are median (25%e75% quartiles) or as otherwise indicated.
comparison test was performed by Scheffe test.
* P<.05 as calculated by comparison with pretreatment.
www.archives-pmr.orgtransplanted cells. Lack of mechanical loading causes bone loss
and fractures in the elderly.29 During physical activity, me-
chanical forces are placed on the bones through ground reaction
forces and the contractile activity of muscles.30,31 Adapting
physical forces to bone structure results in maintenance and
prevention of fractures in the elderly.30 Fluid flow, strain, and
hydrostatic pressure are mechanotransducers of physical force
to osteocytes.29,31,32 Stimulated mechanoreceptors on osteocytes
activate the prostaglandin and Wnt pathways.33 Mechanical
loading stimulates not only osteocytes but also osteoblasts34,35
and MSCs.36,37 Oscillatory fluid flow promotes the prolifera-
tion and differentiation of marrow MSCs.37 Furthermore,, 6 months after treatment, and 12 months after treatment (NZ6)
Size
6mo)
12mo After
Treatment
Effect Size
(Pre/12mo
P at 3 Time Points
(Pre/6mo/12mo)
92.5 (78.8e95)* 1.58 <.05
96.9 (93.8e100)* 1.63 <.05
73 (64.5e81.5)* 3.18 <.05
79.5 (62e88) 0.72 .31
71.9 (62.5e85.9) 0.11 .58
93.8 (78.2e100) 1.00 .21
100 (100e100) 1.15 .13
80 (80e83.4) 0.44 .27
P values at 3 time points were calculated by Friedman test. Multiple
538 T. Aoyama et almechanical signals inhibit adipogenesis and promote the anab-
olism of osteogenesis.36 A report by Ambrosio et al38 reveals
important information about this issue. Treadmill running has a
synergistic effect on healing injured skeletal muscle after
muscle-derived stem cell transplantation,38 in addition to the
positive effects of improved weight management, cardiovascular
health, and metabolic profile.39 Our previous report40 suggested
that adequate exercise promotes muscle remodeling after bilat-
eral broad necrosis of the soleus muscles. It is hypothesized
that suitable mechanical stimulation drives the differentiation of
MSCs, while the beneficial paracrine effect may induce a
synergistic effect between MSC transplantation and rehabilita-
tion. However, further basic and clinical research is required to
prove this hypothesis.
Evaluation of the effect of nonsurgical procedures on ION is
important. Mont et al18 compared the effect of core decompres-
sion surgery with nonsurgical management of ION and reported a
63.5% satisfactory clinical result with core decompression, but
only 22.7% with nonsurgical management. However, this study
was not an adjusted case-control study but was a literature re-
view. Therefore, etiologic factors and radiographic findings were
not fully assessed.18 In multicenter, randomized controlled
studies, physical therapy has similar effects in ION patients with
sickle cell disease as does core decompression surgery with
physical therapy.19,41 Basic studies to design the rehabilitation
protocol and further clinical studies are needed, but the infor-
mation provided from the current study may aid in the devel-
opment of rehabilitation protocols after cell transplantation for
the treatment of ION.
Study limitations
The current study has several major limitations. This was a small-
scale, single-group, pre-post preliminary study. Case-control and
large-scale studies are needed to demonstrate the efficacy of the
rehabilitation protocol. The current study was based on the orig-
inal clinical trial, so it is not an individual study. The population
size of the clinical trial itself was limited because it was a feasi-
bility study.
Conclusions
The present study demonstrated the feasibility and safety of an
intensive multiplex rehabilitation program after MSC trans-
plantation in individuals with ION. Despite this, future studies
should investigate dosing and timing parameters, as well as the
mechanistic basis for improvements in outcomes when a combi-
nation therapy is used.
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Appendix 1 Assessment of Necrotic Lesions
and Stages
Radiographic classification proposed by the SDIC in Japan20:
 Type A lesions occupied the medial one third or less of the
weight-bearing portion.
 Type B lesions occupied the medial two thirds or less of the
weight-bearing portion.
 Both types C1 and C2 lesions occupied more than the medial
two thirds of the weight-bearing portion.
 Type C2 lesions extended laterally to the acetabular edge, but
type C1 lesions did not.
The ION staging proposed by the SDIC used in Japan is a
modified version of the system proposed by the Association
Research Circulation Osseous Committee.20
 Stage 1: Specific findings of osteonecrosis are not observed on
magnetic resonance imaging, bone scintigram, histology, or
radiographs.
 Stage 2: Demarcating sclerosis is seen without collapse of the
femoral head.
 Stage 3: Collapse of the femoral head, including the crescent
sign, is seen without joint-space narrowing. Mild osteophyte
formation of the femoral head or acetabulum may be seen.
 Stage 3A: Collapse of the femoral head <3mm
 Stage 3B: Collapse of the femoral head 3mm
 Stage 4: Osteoarthritic changes are seen.
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